ABX-002 is under clinical development by Autobahn Therapeutics and currently in Phase I for Major Depressive Disorder. According to GlobalData, Phase I drugs for Major Depressive Disorder have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ABX-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABX-002 is under development for the treatment of multiple sclerosis (MS), adrenomyeloneuropathy (AMN), major depressive disorder and treatment resistant depression. It is administered through oral route. It acts by targeting thyroid hormone receptor beta (THRB) and is developed based on brain-targeting chemistry platform.
Autobahn Therapeutics overview
Autobahn Therapeutics is a biotechnology company that discovers and develops small molecule therapies to treat central nervous system disorders. It is investigating its lead molecule ABX-002, a CNS-directed thyroid hormone receptor beta (TRß) agonist against treatment-resistant depression (TRD), multiple sclerosis (MS) and adrenomyeloneuropathy (AMN). The company is also evaluating neurodegenerative and bioenergetic drugs. Autobahn Therapeutics utilizes its brain targeting chemistry platform to create orally administered small molecule prodrugs. It was funded by Arch Venture Partners, Cowen Healthcare Investments, Invus, BVF Partners LP, and Healthcare Capital Partners, among others. Autobahn Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of ABX-002’s drug-specific PTSR and LoA scores, buy the report here.